Figure no. 1 - Global Burden of Hypertention ⁹

Figure no. 2 - Analytical Techniques Used in Antihypertensive Drug Analysis⁹

2. Overview of Antihypertensive Drugs:

The antihypertensive drugs are classified based on their mode of action.

· ACE Inhibitors: Enalapril, Lisinopril, Perindopril

· ARBs: Losartan, Valsartan, Telmisartan

· Beta-blockers: Atenolol, Metoprolol, Propranolol

· Calcium channel blockers: Amlodipine, Nifedipine, Verapamil

· Diuretics: Hydrochlorothiazide, Indapamide

Hypertension refers to a chronic cardiovascular disorder that is characterized by persistent elevation of blood pressure in the arteries and has been identified to be a major risk factor of coronary artery disease, stroke, heart failure, kidney impairment among other vascular complications. Medication is a key element in the successful management of hypertension, and many antihypertensive agents have been developed in order to address various physiological processes that play a role in the regulation of blood pressure. These drugs act by modifying the amount of cardiac output, the resistance of the peripheral vascular bed, the quantity of blood in the body, or the neurohormonal system. The severity of the disease, existing comorbidities, age, and patient response to treatment are some of the factors that influence the choice of the antihypertensive treatment.^10,11

Antihypertensive drugs are typically classified into a few major categories based on their mechanism of action and they include diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), calcium channel blockers (CCBs), beta adrenergic antagonists, alpha adrenergic antagonists, centrally acting agents, and direct vasodilators. Combination therapy, i.e. the use of two or more antihypertensive medications is becoming a normal practice in modern clinical practice to attain greater blood pressure control and reduce side effects.¹²

Angiotensin-Converting Enzyme (ACE) Inhibitors:

ACE inhibitors reduce blood pressure by inhibiting the conversion of angiotensin I into angiotensin II that is a potent vasoconstrictor thereby reducing the vascular resistance and aldosterone secretion. Some of the commonly used ACE inhibitors are enalapril, lisinopril, ramipril, and perindopril. These medicines are particularly beneficial to patients who have diabetes, chronic kidney disease and heart failure because they have protective effects on the kidney and cardiac system. However, this has some side effects such as cough and angioedema which limits its administration on some patients.¹³

Angiotensin II Receptor Blockers (ARBs):

The action of angiotensin II and its interaction with the AT1 receptor are blocked by ARBs, causing vasodilation and the reduction of the aldosterone-mediated retention of sodium. The drugs such as losartan, valsartan, telmisartan, and olmesartan are often given due to their efficacy and better tolerability over ACE inhibitors. ARBs are also extensively used instead of patients not able to tolerate ACE inhibitors, and are commonly used in fixed-dose combinations.¹⁴

Calcium Channel Blockers (CCBs):

Calcium blockers inhibit the entry of calcium ions through L-type calcium channels that are present in vascular smooth muscle and cardiac cells leading to vasodilation and decreased myocardial contractility. CCBs are further divided into two, dihydropyridines (amlodipine and nifedipine) and non-dihydropyridines (verapamil and diltiazem). Dihydropyridine CCBs are employed in the management of hypertension due to their strong vasodilatory properties, but non-dihydropyridines are also used in the management of arrhythmias and angina.¹⁵

Beta-Adrenergic Blockers:

Beta-blockers also lead to a decrease in blood pressure through a decrease in the heart rate, myocardial contractility and renin secretion by the kidneys. Some typical beta-blockers are carvedilol, atenol, metoprolol and propranol. Although beta-blockers have ceased to be the first choice in the treatment of uncomplicated hypertension, they continue to play a major role in patients who are already ischemic heart disease, heart failure, and who have a myocardial infarction history. Their management requires close observation because of potential side effects (metabolic and respiratory) they can cause.¹⁶

Alpha-Adrenergic Blockers and Centrally Acting Agents:

Alpha-adrenergic antagonists such as prazosin and doxazosin reduce the peripheral vascular resistance by blocking alpha1 receptors in blood vessels. The central nervous system medications, e.g. clonidine and methyldopa, assist in controlling blood pressure levels by slowing down the activity of the sympathetic nervous system. There is general use of these medications as second- or third-line agents because they have side effects, however they are significant in specific clinical situations.¹⁷

Combination Therapy and Fixed-Dose Combinations:

The contemporary form of hypertension treatment is more focused on the application of combination therapy as a form of enhancing blood pressure levels and compliance levels among the patients. Fixed doses of combinations of antihypertensive medications should be used e.g. ACE-inhibitors with diuretics or ARBs with calcium channel blockers and have synergistic benefits, in addition to decreasing the number of pills that patients are required to take. These are formulations that are analytically difficult and have multiple active pharmaceutical ingredients and this is to imply that methods development and methods validation must be sound.¹⁸

3. Analytical Method Development:

The evolution of analytical techniques is a scientific and systematic operation with the goal of the evolution of dependable, correct and consistent strategies of determining, quantifying and depicting pharmaceutical compounds. The creation of procedures in relation to the antihypertensive medicines is a critical subject matter in regard to quality, safety, and therapeutic effectiveness of the drug throughout the lifecycle. Along with the high level of diversity of various structures and different physicochemical characteristics and the frequent utilization of fixed-dose combinations, the establishment of powerful methods of analysis of antihypertensive medications is an exclusive and complicated issue.^19,20

The general aim of development of analytical methods is to develop a process that serves the purpose of the process itself whether it is a routine quality control process, stability work, impurity profiling process, dissolution work process or bio analytical work process. An adequately designed technique should be in position to isolate active pharmaceutical ingredient (API) amid excipients, impurities and degradation byproducts with selectivity and offer a sensitive and definite quantitative information. The regulatory bodies stress that the scientifically proven analytical procedures should be documented and capable of providing reproducible results to the varied analytical conditions.²¹

3.1 Pre-Method Development Considerations:

The process of developing methods entails, first, a clear cut image of the drug product and drug substance. Such important data as the chemical structure, weight, pK a, solubility, polarity and stability profile of antihypertensive drugs need to be evaluated. The majority of the antihypertensive medications such as the ACE inhibitors and the ARB are not aqueous soluble and are sensitive to pH changes, light or oxidative conditions. These properties play important role in the determination of the methods of analysis to be used and the conditions of the experimentation.²²

Development approach is determined by the objective of the approach. To illustrate this point, the techniques applied in assay identification are varied when applied in the impurity analysis or stability analysis. Where a combination formulation is involved, the method should be capable of effectively separating multiple active pharmaceutical ingredients (APIs) with different chemical properties in a single analytical. The requirements are the close optimization of the chromatography and detection parameters.²³

3.2 Selection of Analytical Technique:

The type of instrument that will be used in the analysis relies on the type of analyte, the sensitivity that is required, the instrumentation that is available and what is anticipated of it by the regulating body. UV-Visible spectrophotometry is the other technique widely used in the primary research and analysis as it is simple, inexpensive and provides quick analysis. It is not comprehensive though, so this is one of its drawbacks in the application of complex formulations and stability tests.²⁴

Chromatographic techniques are perceived to be the common approach and more so, the High-Performance Liquid Chromatography (HPLC), due to their simplicity and effectiveness. HPLC is very resolute, sensitive and reproducible and can therefore be employed in single and multi-component formulation. Modern techniques such as Ultra-Performance Liquid Chromatography (UPLC) permit quicker analyses, less solvent usage and high productivity whilst the coupled methods such as LC-MS /MS have the ability to detect the structure and determine impurities and metabolites at low concentrations.²⁵

3.3 Chromatographic Method Development:

Various important parameters would require a progressive process to establish chromatographic methods to conduct effective separation and precise quantification. A choice of stationary phase is a fundamental procedure and reversed-phase C18 columns are the most popular, as it has the broadest variety of applications and can be utilized with an enormous quantity of antihypertensive agents. Otherwise, selectivity might be enhanced by incorporating different stationary phases in order to achieve better results like C8 stationary phase, phenyl or cyano column.²⁶

The mobile phase composition matters in the retention time determination, shape of the peaks, and resolution. Mobile phases are typically composed of aqueous buffer and organic solvents, e.g. methanol or acetonitrile. The ionizable drugs especially are especially susceptible of the pH of the buffer as it has an effect on the extent of ionization and the interaction of the ionized drug with the stationary phase. Gradient elution is usually applied when the formulation contains more than one component, and impurity analysis to enhance the efficiency of separation.²⁷

The flow rate, column temperature and injection volume are other variables that ought to be optimized accurately. The type of detector to use depends on the characteristics of the absorption and sensitivity requirement of the analyte and might be UV, PDA, fluorescence or mass spectroscopical detector. The capacity of determining the wavelength to be applied in UV detection is normally affected by the highest potential absorbance of the drug to give it maximum sensitivity.²⁸

3.4 Development of Stability-Indicating Methods:

It is also a significant element of the development of analytical tools to antihypertensive drugs that stability-measuring tools are developed. The aims of such methods are valid identification of the active pharmaceutical ingredient (API) in the existence of its degradation by-products, and provide a trustworthy evaluation of stability. The forced degradation studies simulate different stress conditions to assess the degradation behavior of the drug since different environments can be tested like acidic, alkaline, oxidative, thermal, and photolytic.^29,30

This approach must be in a way that the distance between the active pharmaceutical ingredient (API) and the degradation products is sufficiently wide to ensure that there is no interference with the retention time of the API. The stability indicative procedures are critical in the stability of the shelf-life determination, the formulation optimization and the regulatory submission preparations. These techniques need to be developed through an in-depth insight into the degradation processes and accuracy of modification of the chromatography parameters.³¹

3.5 Challenges in Method Development for Antihypertensive Drugs:

The development of analytical techniques of antihypertensive drugs may be complicated by the low dosage levels, intersections of chromatographic peaks with other drugs in combination, and even the presence of chemically related impurities. Moreover, the necessity of fast analysis and environmentally-friendly activities presupposes the constant process of further innovation and improvement.³²

In short, the analytical methods of antihypertensive drugs development is a critical and complicated task which needs scientific accuracy, regulatory expertise, and technical proficiency. An adequately designed analytical procedure does not only ensure the reliability of quality management but also contributes to the compliance with the regulations and the protection of the patient.³³

4. Analytical Method Validation:

Validation of analytical methods is a crucial and obligatory procedure in pharmaceutical analysis that provides documented proof confirming that an analytical method is appropriate for its intended use. When analyzing antihypertensive medications, method validation guarantees that the established analytical techniques consistently produce trustworthy, accurate, precise, and reproducible results when utilized on bulk drug substances, pharmaceutical products, and, when relevant, biological samples. Regulatory agencies around the globe mandate validated analytical methods to ensure product quality, ensure patient safety, and meet established quality standards.³⁴

The growing intricacy of antihypertensive drug formulations, such as fixed-dose combinations and products with low-dose strengths, has heightened the significance of thorough method validation. Validation verifies that the analytical method operates effectively under specified conditions and can identify changes in drug content, impurities, and degradation products during the lifecycle of the product.³⁵

4.1 Regulatory Framework for Method Validation:

In order to ensure uniformity and international acceptance of pharmaceutical products, international validation of methodologies is guided by international regulatory requirements. The best-known guideline is the International Council for harmonisation (ICH) guideline Q2 (R1), which gives the criteria used in the validation of analytical procedures used in quality control testing. Additional information and advice can be obtained through regulatory bodies, including the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the World Health Organization (WHO).³⁶

According to the ICH Q2 (R1) requirements, the validation criteria depend on the purpose of the analytical method, which can be the identification, assay, impurity testing, or the dissolution analysis. These guidelines are important in regulatory submissions including new drug applications, abbreviated new drug applications and post-approval modifications.³⁷

4.2 Types of Analytical Methods Requiring Validation:

The analytical methods applied to the antihypertensive drugs could be tests involved in identification, quantification, analysis of impurities and degradation, and bio analytical methods. All categories require the assessment of certain parameters. An example action would be to have assay methods focus on accuracy and precision whereas impurity testing is focused on sensitivity, specificity and detection thresholds. The stability indicating techniques require careful validation as to ensure they are able to differentiate the drug and degradation products.³⁸

4.3 Validation Parameters as per ICH Guidelines:

4.3.1 Specificity:

Specificity refers to the ability of an analytical method to identify the target analyte clearly in the presence of other substances such as impurities, degradation products and excipients in the formulation. Specificity is also important in the case of antihypertensive drugs due to frequent occurrence of combination regimens and structurally analogous impurities. The chromatographic methods should provide a clear difference among the peaks so that there is no interference at the retention time of the analyte.³⁹

4.3.2 Linearity and Range:

The Linearity indicates the ability of the method to produce test results that are directly proportional to the concentration of the analyte in a given range. Standard solutions are typically tested to evaluate it at varying concentrations. The range is calculated based on the application of the method, and normally rate is between 80-120 percent of the desired concentration of assay protocols. The presence of good correlation coefficient indicates good linearity in the analysis of antihypertensive drugs.⁴⁰

4.3.3 Accuracy:

Precision measures the degree to which the value obtained is nearer to the actual value as the analytical method has established. This is normally determined by recovery studies whereby accurate doses of the drug are added to the sample matrix under different concentrations. Mechanisms of reliability are essential in ensuring correct dosages and effectiveness of the antihypertensive drugs.⁴¹

4.3.4 Precision:

Precision determines the degree to which the results of the individual tests are consistent when the method is used repeatedly under specified conditions. It includes repeatability (intra-day accuracy), intermediate accuracy (inter-day, different analysts or instruments) reproducibility. Low relative standard deviation values indicate high levels of precision, which are essential in the everyday quality control testing program.⁴²

4.3.5 Limit of Detection (LOD) and Limit of Quantification (LOQ):

LOD is the lowest concentration at which an analyte can be observed but not quantified whereas LOQ indicates the lowest concentration that can be measured accurately with a reasonable level of certainty. These measures are particularly important in characterizing impurities and stability testing of antihypertensive drugs in which very small concentrations must be included.⁴³

4.3.6 Robustness:

Robustness reflects how an analytical method can remain constant even when small, purposeful variations in method parameters such as pH, flow rate, column temperature or the content of the mobile phase occur. Strong methods have fewer chances of failure in regular functioning and can provide more confidence on the results of the analysis.⁴⁴

4.3.7 System Suitability Testing:

System suitability tests are carried out to ensure that the system of analysis is running to the correct operational standard before the analysis of samples is carried out. Issues like resolution, tailing factor, theoretical plates and consistency of retention time are evaluated in a bid to ensure reliable method performance.⁴⁵

4.4 Validation of Stability-Indicating Methods:

Stability indicating methods require extensive validation to ensure that they can properly measure the drug in the presence of drug degradation products. Forced degradation experiments are conducted in order to develop potential degradants and the process should be able to distinguish between them and the active pharmaceutical ingredient. These techniques are important in validating to ascertain shelf-life and compliance to regulatory standards.⁴⁶

4.5 Challenges in Method Validation for Antihypertensive Drugs:

The analysis of antihypertensive drugs presents challenges, including low-dose strengths, matrix interference, and overlapping chromatographic peaks in combination solutions. Also, it requires a close optimization and validation to obtain a sensitivity to detect impurities and at the same time make the process simple.⁴⁷

5. Recent Advances:

The world of analytical sciences has had a major shift during the last few decades. These innovations have been enhanced by the increased regulatory standards, need to have quality assurance that is more efficient, technological advancements and environmental sustainability. These advances have made the identification and measurement of active pharmaceutical ingredients (APIs), impurities, decomposition products and trace metabolites significantly easier in the analysis of antihypertensive drugs where precision, sensitivity and reliability are of vital concern. The section engages in discussing the most important recent innovations in the development and validation of analytical methods, their principles, uses, and benefits.⁴⁸

5.1 Adoption of Hyphenated and High-Resolution Techniques:

An important more recent development in the field of the analytical methods is the implementation of separations methods in combination with advanced detectors to form so-called hyphenated systems. These techniques combine the separation properties of chromatography with the structural analysis properties of mass spectrometry that provide excellent analytical performance.⁴⁹

LC-MS/MS (Liquid chromatography-tandem mass spectrometry) has appeared as a basic method of bioanalysis and profiling impurities. Its impressive specificity enables the combined determination of multiple antihypertensive drugs and their metabolites in complex matrices including plasma and urine with a high level of sensitivity sometimes in the ng/mL range.⁵⁰

The resolution and precise determination of the mass using UPLC-QToTF (Ultra-Performance Liquid Chromatography combined with Quadrupole Time-of-Flight Mass Spectrometry) are extremely high, which is why it can be used especially in the structural analysis of degradation products, impurities, and unknown substances.⁵¹

Non-volatile antihypertensive drugs are less commonly analyzed by GC-MS (Gas Chromatography-Mass Spectrometry), although derivatization can be used when making the drug more volatile, particularly in sample trace analysis in metabolic studies.⁵²

5.2 Green Analytical Chemistry (GAC):

The concept of sustainability has become a central concept of modern analytical science. Green Analytical Chemistry (GAC) is a pursuit aimed at reducing the environmental impact of analytical procedures through the reduction of the use of toxic solvents, reduction of energy consumption as well as generation of lesser chemicals. The key green plans include:

Miniaturization: Minimizing the use of solvents and samples is done through micro- or nano-scale chromatography.

Reduction and Substitution of Solvents: The use of less toxic solvents like aqueous mobile phases, ethanol, and others instead of traditional organic solvents like acetonitrile and methanol.

Solid-Phase Microextraction (SPME): This is a sample preparation technique that does not use any solvents and is therefore less sensitive and kind to the environment.⁵³

5.3 Application of Chemometrics and Multivariate Data Analysis:

Chemometrics uses statistical and mathematical methods to complement analytical methods and provide meaning to complex data. The applications that are important include:

Spectroscopy analyzes using multivariate analyzer techniques (e.g. PLS and PCA).

Design of Experiments (DoE), which permits the successful evaluation of multiple variables.

Pattern recognition for analyzing impurity profiles and stability trends.⁵⁴

5.4 Bioanalytical Advances and Micro-Sampling Techniques:

In pharmacokinetics and therapeutic drug monitoring studies, current progress in bioanalysis gains more and more relevance:

DBS sampling has less invasiveness and can be easily stored.

Minimally invasive methods like microdialysis increase the real time monitoring abilities.

LC-MS/MS methods based on microflow or nanoflow can be used to detect minute volumes of samples.⁵⁵

Table No 2- Impact of Recent Advances⁵⁶

Category	Key Benefit	Typical Application
Hyphenated Techniques	High sensitivity and specificity	Impurity profiling, bioanalysis
Green Analytical Chemistry	Reduced environmental impact	Routine QC, method sustainability
Quality by Design	Increased robustness	Method development and validation control
High-Throughput Automation	Consistency, speed	Routine pharmaceutical testing
Chemometrics	Efficient optimization	Data interpretation and DoE
Bioanalytical Micro-Sampling	Less invasiveness	PK studies, therapeutic monitoring
AI/ML Tools	Predictive analytics	Future method design

6. Challenges:

Despite significant progress in the construction of analytical techniques of anti-hypertensive drugs and their validation, there are a lot of scientific, technical, and regulatory obstacles, which continue to challenge the accuracy and efficacy of pharmaceutical analysis. An increase in the complexity of the drug formulations, the rise in regulatory control, and changes in expectations regarding sustainability and digitalization demand continuous innovation. Under this section, the key challenges experienced in an analytical evaluation of antihypertensive drugs have been brought to the limelight and the future trends have been listed, which are likely to come into play in this field.^57-59

6.1 Challenges in Analytical Method Development and Validation:

6.1.1 Complexity of Fixed-Dose Combination Formulations:

The fact that the use of fixed-dose combinations is widespread in the study of antihypertensive drugs is one of the greatest limitations to this research since there are two or more active pharmaceutical ingredients with different physicochemical properties. The difference in polarity, solubility, pKa, and stability often results in overlapping chromatographic peaks and insufficient resolution and sensitivity variability. Development of a coherent analytical technique that is capable of measuring all the components without interfering with each other remains a major analytical challenge.^60,61

6.1.2 Low Dosage Strength and Sensitivity Requirements:

Regulatory authorities are laying increasingly heavy emphasis on the all-inclusive impurity profiling, which entails the determination and measurement of trace-level contaminants and degradation byproducts. Antihypertensive drugs are often degraded by hydrolytic, oxidative, and photolytic reactions to structurally analogous degradation products which are difficult to separate and identify. It is a complex and resource intensive task to develop stability-indicating techniques that are able to distinguish all the relevant components correctly.^62,63

6.1.3 Method Robustness and Transferability:

It is expected that in the future, the development of analytical methods will more and more include the principles of Quality by Design. Setting up a method operable design region and implementing continuous performance monitoring would enhance method robustness and encourage regulatory plasticity. Lifecycle management strategies will ensure approaches remain reliable at all the product development and commercialization phases.^64-66

7. Future Perspective:

The forthcoming improvements in analytical methodology and validation of antihypertensive drugs will be aimed at the strength, durability, and digital transformation. Combining the ideas of Analytical Quality by Design and method management based on the lifecycles will increase the reliability of methods and their regulatory flexibility. The development of new technologies like ultra-high-performance liquid chromatography combined with high-resolution mass spectrometry will enhance profiling of impurity and trace-level detection especially of fixed-dose combination products. Laboratory practices will be environmentally friendly, with the adoption of greener methods of analytical chemistry, such as low amounts of solvents used, and shrunk analytical systems. Moreover, it is expected that the automation, artificial intelligence, and machine learning tools will facilitate optimizing the methods, enhancing the data interpretation, and predicting degradation models. As the focus on data integrity is growing, and regulatory harmonization across all possible global regions is established, the risk-based assessment and ongoing performance validation will be integrated into future validation strategies. In general, the development of modern techniques of analyzing with the use of sustainable and digital solutions will substantially enhance the quality assurance systems and safe and effective use of antihypertensive drugs.

8. CONCLUSION:

The development and validation of the analytical method are indispensable elements of the quality assurance of antihypertensive drugs as drugs. Given the worldwide morbidity and pathos of hypertension and lifelong use of antihypertensive treatments, the development of sensitive, reliable, and regulatory-compliant analysis protocols is a matter of outstanding concern. Effective quantification of active pharmaceutical constituents and effective detection of impurities and degradation products can be achieved through appropriate method development, which is based on a comprehensive knowledge of physicochemical properties and performing systematic maximization of the conditions of the analysis. The chromatographic methods especially high-performance liquid chromatography and hi-tech hyphenated methods are still the most dominant because they are highly selective, sensitive and reproducible. Also, validation following internationally harmonized standards gives documented records of the suitability of methods, can be consistent between development and regulatory submission and routine quality control settings. The new trends, the lifecycle-based validation strategies, green analytical considerations and digital developments are likely to enhance the robustness of analytics further. In general, further development of analytical methodologies is required to meet the complexity of formulation, developing demands of regulatory expectations, and increasing pharmaceutical quality evaluation requirements in the treatment of antihypertension with drugs.

9. REFERENCES:

1. Alshora, D. H., Sherif, A. Y., and Ibrahim, M. A. Development and validation of a UPLC method for simultaneous estimation of antihypertensive drugs in fixed-dose combinations. Processes. 2024; 12(6): 1259. https://doi.org/10.3390/pr12061259

2. Attia, K. A. M., Abdel-Monem, A. H., Abdel-Raoof, A. M., and El-Sayed, H. M. Highly sensitive HPLC method for cardiovascular drugs using dual detection. Scientific Reports. 2025; 15: 12229. https://doi.org/10.1038/s41598-025-94907-0

3. Blessy, M., Patel, R. D., Prajapati, P. N., and Agrawal, Y. K. Development of forced degradation and stability-indicating studies of drugs—A review. Journal of Pharmaceutical Analysis. 2014;4(3): 159–165. https://doi.org/10.1016/j.jpha.2013.09.003

4. El Karbane, M., and Benchekroun, Y. H. UPLC-DAD method for simultaneous determination of antihypertensive drugs. Journal of AOAC International. 2021; 104(3): 562–570.

5. Gorog, S. The importance of impurity profiling of pharmaceutical products. TrAC Trends in Analytical Chemistry. 2018;101: 2–10.

6. ICH Harmonised Guideline. Validation of analytical procedures: Text and methodology Q2 (R1). International Council for Harmonisation. 2005.

7. ICH Harmonised Guideline. Q14: Analytical procedure development (Draft). International Council for Harmonisation. 2019.

8. International Conference on Harmonisation. ICH Q2 (R1) validation of analytical procedures. ICH Secretariat. 2005.

9. Kazakevich, Y., and Lobrutto, R. HPLC for pharmaceutical scientists. Wiley-Interscience. 2007.

10. Khuroo, A. H., and Monif, T. Regulatory perspectives on analytical method validation. Journal of Pharmaceutical Sciences. 2020; 109(1): 35–42.

11. Kumar, N., and Singh, R. Analytical techniques for antihypertensive drugs: A review. Asian Journal of Pharmaceutical Sciences. 2019; 14(6): 609–623.

12. Li, K., Wen, Y., and Chen, J. Application of LC–MS/MS in pharmaceutical analysis. Journal of Chromatography B. 2021; 1178: 122809.

13. McPolin, O. An introduction to HPLC for pharmaceutical analysis. Mourne Training Services. 2009

14. Meyer, V. R. Practical high-performance liquid chromatography (4th ed.). Wiley. 2010

15. Patel, B. N., Sharma, N., Sanyal, M., and Shrivastav, P. S. Stability-indicating methods in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis. 2018; 147: 39–58.

16. Ranganath, M. K., Sudha, P. D. C., Ramesh, G., and Dang, R. HPLC method development and validation of antihypertensive drugs. Indian Journal of Pharmaceutical Education and Research. 2024; 58(3): 1053–1061.

17. Rashid, M. A., Shazly, G., and Kazi, M. UHPLC-UV method for valsartan and nifedipine. Separations. 2022; 9(11) : 325.

18. Snyder, L. R., Kirkland, J. J., and Dolan, J. W. Introduction to modern liquid chromatography (3rd ed.). Wiley. 2010.

19. Skoog, D. A., Holler, F. J., and Crouch, S. R. Principles of instrumental analysis (6th ed.). Cengage Learning. 2014.

20. Swartz, M. E., and Krull, I. S. Analytical method development and validation. CRC Press. 2018.

21. United States Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics. FDA. 2015.

22. World Health Organization. WHO guidelines on pharmaceutical quality control. WHO Press. 2018.

23. Sebaiy, M. M., El-Adl, S. M., and Baraka, M. M. QbD-based RP-HPLC method for antihypertensive drugs. BMC Chemistry. 2022; 16: 70.

24. Tang, D., and Row, K. H. Green analytical chemistry in pharmaceutical analysis. Journal of Separation Science. 2019; 42(1): 1–14.

25. Tong, C., and Xu, X. Application of chemometrics in analytical method optimization. Analytical Methods. 2020; 12: 4210–4222.

26. Venkataraman, S., and Haritha, G. Chromatographic separation of antihypertensive drugs. Asian Journal of Pharmaceutical and Clinical Research. 2018; 11(9): 112–118.

27. Yadav, M., and Rao, R. N. Impurity profiling of pharmaceutical products. Journal of Pharmaceutical Analysis. 2019; 9(1): 1–15.

28. Yelmame, S. S., and Amrutkar, S. V. Validation of RP-HPLC dissolution method as per ICH. European Journal of Life Sciences. 2024; 3: 93–100.

29. Zhou, X., and Chen, Y. Advances in bioanalytical LC–MS/MS methods. Bioanalysis. 2021; 13(4): 267–281.

30. Kothapalli, L., and Subramanian, G. Stability studies in pharmaceutical analysis. Journal of Pharmaceutical Sciences. 2017; 106(9): 2284–2294.

31. Ahuja, S., and Rasmussen, H. HPLC method development for pharmaceuticals. Elsevier. 2007.

32. Ermer, J., and Miller, J. H. M. Method validation in pharmaceutical analysis. Wiley-VCH. 2005

33. Nagy, K., and Szepesi, G. Regulatory aspects of analytical method validation. Journal of Chromatography A. 2016; 1458: 1–9.

34. Rao, P. V., and Murthy, T. E. G. K. UV spectrophotometric analysis of antihypertensive drugs. International Journal of Pharmaceutical Sciences Review and Research. 2018: 51(2): 45–52.

35. Blessy, M., and Agrawal, Y. K. Analytical challenges in combination drug products. Journal of Pharmaceutical Analysis. 2015; 5(4): 211–223.

36. Zhang, H., and Wang, Y. Automation in pharmaceutical analytical laboratories. TrAC Trends in Analytical Chemistry. 2022; 150: 116579.

37. Shaikh, K. A., and Patil, A. T. Development of stability-indicating HPLC methods. Journal of Pharmaceutical Research International. 2020; 32(12): 21–31.

38. Iqbal, M., and Hussain, T. Analytical challenges in fixed-dose combination drugs. Future Journal of Pharmaceutical Sciences. 2021; 7: 156.

39. Rao, R. N., and Nagaraju, V. An overview of stability-indicating HPLC methods. Journal of Pharmaceutical and Biomedical Analysis. 2003; 33(3): 335–377.

40. World Health Organization. Guidelines on stability testing of pharmaceutical products. WHO. 2021.

41. Blessy, M., Patel, R. D., Prajapati, P. N., and Agrawal, Y. K. Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis. 2014; 4(3): 159–165.

42. ICH Q1A(R2). Stability testing of new drug substances and products. International Council for Harmonisation, Geneva. 2003.

43. ICH Q2(R1). Validation of analytical procedures: Text and methodology. International Council for Harmonisation, Geneva. 2005.

44. ICH Q8(R2). Pharmaceutical development. International Council for Harmonisation, Geneva. 2009.

45. ICH Q9. Quality risk management. International Council for Harmonisation, Geneva. 2005.

46. ICH Q10. Pharmaceutical quality system. International Council for Harmonisation, Geneva. 2008.

47. Snyder, L. R., Kirkland, J. J., and Dolan, J. W. Introduction to Modern Liquid Chromatography (3rd ed.). Wiley. 2010.

48. Swartz, M. E., and Krull, I. S. Analytical Method Development and Validation. CRC Press. 2012.

49. Kazakevich, Y., and LoBrutto, R. HPLC for Pharmaceutical Scientists. Wiley. 2007.

50. Dong, M. W. Modern HPLC for Practicing Scientists. Wiley. 2016.

51. Bakshi, M., and Singh, S. Development of validated stability-indicating assay methods—critical review. Journal of Pharmaceutical and Biomedical Analysis. 2002; 28: 1011–1040.

52. Ermer, J., and Miller, J. H. Method Validation in Pharmaceutical Analysis. Wiley-VCH. 2005.

53. Ravisankar, P., et al. A review on analytical method development. Indian Journal of Research in Pharmacy and Biotechnology. 2015; 3(2): 130–142.

54. Skoog, D. A., Holler, F. J., and Crouch, S. R. Principles of Instrumental Analysis (6th ed.). Cengage Learning. 2018.

55. Willard, H. H., Merritt, L. L., Dean, J. A., and Settle, F. A. (Instrumental Methods of Analysis. CBS Publishers. 2004.

56. Ahuja, S., and Dong, M. W. Handbook of Pharmaceutical Analysis by HPLC. Elsevier. 2005.

57. Carstensen, J. T., and Rhodes, C. T. Drug Stability: Principles and Practices. Marcel Dekker. 2000.

58. Baertschi, S. W., et al.). Pharmaceutical Stress Testing. Informa Healthcare. 2011.

59. Chatwal, G. R., and Anand, S. K. Instrumental Methods of Chemical Analysis. Himalaya Publishing House. 2014.

60. Jeffery, G. H., et al. Vogel’s Textbook of Quantitative Chemical Analysis (5th ed.). Longman. 1989.

61. Miller, J. N., and Miller, J. C. Statistics and Chemometrics for Analytical Chemistry. Pearson. 2010.

62. Bolton, S., and Bon, CPharmaceutical Statistics: Practical and Clinical Applications. CRC Press. . 2010.

63. Taverniers, I., et al. Trends in quality in the analytical laboratory. TrAC Trends in Analytical Chemistry. 2004; 23(8): 535–552.

64. Rozet, E., et al. Analytical method validation and total error concept. Journal of Pharmaceutical and Biomedical Analysis. 2011; 55: 848–858.

65. Singh, S., and Bakshi, M. Guidance on conduct of stress tests. Pharmaceutical Technology. 2000; 24(2): 1–14.

66. Rao, R. N., and Nagaraju, V. Stability indicating HPLC methods—review. Journal of Pharmaceutical and Biomedical Analysis. 2003; 33: 335–377.

Received on 04.04.2026 Revised on 08.05.2026

Accepted on 10.06.2026 Published on 10.07.2026

Available online from July 25, 2026

Asian Journal of Pharmaceutical Analysis. 2026; 16(3):210-218.

DOI: 10.52711/2231-5675.2026.00032

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

Drug	Combination	Method	Detector	Year	Reference
Amlodipine	With Valsartan	RP-HPLC	UV	2023	Sharma et al., 2023
Telmisartan	With HCTZ	UPLC	PDA	2022	Rao et al., 2022
Losartan	Single	LC-MS/MS	MS	2024	Kumar et al., 2024